32 results about "Fusion gene" patented technology

The application relates to a sarcoma fusion gene nanopore sequencing primer set and application thereof, wherein the primer set comprises five pairs of specific primers (Primer 1-5) with fixed sequences, each primer follows the design principle of 18-25 bp in length, 40%-60% in GC content and strict matching of a target sequence at a 3' end, and the length of an amplification product is 300-800 bp, which is suitable for nanopore sequencing. Through qPCR verification, the primer set has single-peak melting curves, close-to-100% amplification efficiency, strong specificity and excellent amplification performance.

Compositions and methods for knocking down the expression of an EWSR1-ATF1 fusion gene and / or an EWSR1-CREB1 fusion gene in a subject are disclosed herein. In some embodiments, the composition comprises an expression vector comprising a bifunctional short hairpin RNA (bi-shRNA) sequence specific for knockdown of an EWSR1-ATF1 fusion gene and / or an EWSR1-CREB1 fusion gene.

This invention belongs to the field of acute lymphoblastic leukemia (ALL) technology and discloses an ALL scoring system. The system divides the entire treatment cycle into three major phases: induction remission, consolidation therapy, and maintenance therapy. Each phase is further subdivided into sub-phases, forming a two-tiered data acquisition architecture. During data collection, baseline data such as age and fusion genes are included, along with dynamic data such as the rate of MRD decline and drug exposure concentration. Simultaneously, anchor triggering mechanisms are set at different sub-phases, making the risk score more closely aligned with the patient's real-time condition and providing a more accurate reference for clinical treatment strategy selection. The feature adaptation module matches subtype-specific biomarkers and analyzes the interaction between rare subtypes and comorbidities. The matching module calls upon a three-dimensional protocol library to select standardized protocols for common subtypes, targeted protocols for rare subtypes, and dose adjustment or drug substitution protocols for patients with comorbidities, matching more suitable protocols for different patients.

In some embodiments, a computer-implemented method of detecting a presence of a predetermined fusion gene in a biological sample is provided. A computing system generates an alignment of a read sequence to a reference genome. The alignment includes a first alignment result and a second alignment result. The computing system determines a breakpoint location indicated by the first alignment result and the second alignment result, distances between coordinates of the breakpoint location and coordinates of one or more expected breakpoint locations associated with the predetermined fusion gene, a gap size value and an overlap size value. In response to determining that the gap size value is less than a gap size value threshold, the overlap size value is less than an overlap size value threshold, and the distances are less than a breakpoint distance threshold, the computing system generates an indication of the presence of the predetermined fusion gene.

This application relates to the field of molecular pathology diagnostic technology, specifically disclosing a bone marrow smear FISH detection kit and its application. The kit includes a rapid hybridization buffer, a stabilization pretreatment solution, room temperature hybridization probes, probe dilution buffer, low-salt washing buffer, high-salt washing buffer, counterstaining solution, positive control samples, and negative control samples. The room temperature hybridization probes include broken probe pairs targeting the BCR-ABL, PML-RARA fusion genes, and IgH gene rearrangements. The detection method of this kit includes sample pretreatment, probe denaturation, room temperature hybridization, washing and counterstaining, and signal interpretation. Through the synergistic effect of the rapid hybridization buffer and the short-chain low-Tm value probes, rapid hybridization at room temperature is achieved, eliminating the need for a dedicated isothermal hybridization instrument. The stabilization pretreatment solution can complete cell permeation and RNA removal in one step, resulting in a high degree of operational standardization.

The application provides a kit and method for detecting common fusion genes of lymphoid leukemia based on a multiple digital PCR method. By constructing a synergistic mechanism of primers and fluorescent probes, optimizing the collocation of primers, probes and fluorescent markers, and effectively avoiding the non-specific binding between amplification products. The innovative introduction of a composite reaction aid with a specific formula, namely a PCR enhancer, significantly improves the amplification efficiency and specificity of the multiple detection system. The kit provided by the application realizes the integrated detection capability of seven fluorescent channels, Atto 425, VIC, FAM, ROX, CY5, CY5.5 and CY7 in a single hole design. By innovatively constructing a ROX+CY5 and Atto 425+VIC dual-channel combined detection system, when the ROX and CY5 channels or the Atto 425 and VIC channels in the same detection hole simultaneously present positive signals, two additional detection targets can be specifically interpreted. This innovative detection strategy based on channel combination enables the kit to break through and achieve accurate detection of 18 fusion genes with only 2 detection holes.

This invention discloses a dual-targeting DNA vaccine delivery system based on calcium phosphate lipid nanoparticles, belonging to the field of biomedicine. The delivery system comprises calcium phosphate containing histone H1 and an HPV E6 / E7 fusion gene plasmid, and a lipid bilayer membrane of DSPE-PEG-2000-Mannose. This system achieves targeted uptake by dendritic cells through mannose modification and relies on histone H1-mediated DNA nuclear transport. The dual targeting significantly enhances antigen expression efficiency. In vitro and in vivo experiments have demonstrated that this delivery system exhibits good biocompatibility and high stability, effectively activating antigen-specific T-cell immune responses, and possesses both HPV infection prevention and cervical cancer treatment effects, providing a new strategy for cervical cancer prevention and treatment.

The application belongs to the field of microbial metabolic engineering and industrial biotechnology, and relates to a high-activity yeast engineering bacterium and a construction method and application thereof. The high-activity yeast engineering bacterium integrates a fusion gene I on the chromosome of a Saccharomyces cerevisiae starting strain; the fusion gene I encodes a fatty acyl-CoA reductase gene MaFAR1 from 5' to 3'. The base sequence of the fatty acyl-CoA reductase gene MaFAR1 is shown in SEQ ID NO:1. The high-activity yeast effectively improves cell viability and fatty alcohol synthesis capacity.

This invention discloses a recombinant plasmid pULK for treating renal fibrosis, its preparation method, and its applications. The recombinant plasmid pULK carries a Klotho-specific ligand peptide, a GGGGS flexible linker peptide, and a USP2 coding sequence tandemly in a 5'→3' configuration. The amino acid sequences are MASDPLGVVR, GGGGS, and the corresponding USP2 sequence, respectively. The preparation method includes fusion gene design and synthesis, vector linearization, recombinant construction and transformation, and positive clone verification. This plasmid can target and stabilize the Klotho protein, avoiding off-target risks, and can be used to prepare anti-renal fibrosis drugs. It is applicable to various chronic kidney diseases with renal fibrosis, filling a technological gap and demonstrating strong feasibility for clinical translation.

A method for improving the synthetic ability of *Yersinia lipolytica* to synthesize amino acid derivatives. This invention discloses an engineered strain for the biological synthesis of the amino acid derivative β-hydroxy-β-methylbutyric acid (β-methylbutyric acid) and its construction method. Using *Yersinia lipolytica* as the substrate cell, the HMGCL and OCT genes involved in branched-chain amino acid metabolism in its genome are knocked out to obtain a gene knockout strain. Decarboxylase genes, hydratase genes, dehydratase genes, and thioesterase genes are integrated into the genome of the gene knockout strain to obtain an engineered strain capable of de novo synthesis of β-hydroxy-β-methylbutyric acid. Further integration of the CcGCTB-CcGCTA fusion gene expression module enhances the expression level of key enzyme genes, thereby increasing the yield of β-hydroxy-β-methylbutyric acid in the strain. The engineered strain constructed in this invention can synthesize the target product β-hydroxy-β-methylbutyric acid using glucose as a carbon source through fermentation, with a maximum yield of up to 30 g / L.

This invention belongs to the field of genetic engineering and relates to a fusion-type halophilic archaea chitinase, its preparation method, and its applications. Based on chitinase domains from different halophilic archaea, this invention uses overlap extension PCR technology to fuse a chitin-binding domain with strong substrate-binding ability with a catalytic domain with high catalytic activity, thereby constructing a fusion gene. chiB A fusion-type chitinase was obtained through expression and purification. This fusion-type chitinase possesses both catalytic activity and substrate-binding ability, exhibiting excellent degradation efficiency for natural chitin substrates, as well as good salt tolerance and resistance to metal ions, organic solvents, and surfactants. The prepared enzyme can not only be used for chitin degradation, but the degradation products can also be used to prepare chitosan oligosaccharides or N-acetylglucosamine, showing broad market application prospects.

The application discloses a kit for detecting a BMX-ARHGAP fusion gene and application thereof. The application obtains a new fusion gene BMX-ARHGAP from gastric cancer tissues through RNA-seq high-throughput sequencing technology, designs specific primer pairs (SEQ ID NO: 1-2), and establishes a detection method based on RT-qPCR. Research finds that the fusion gene exists in the gastric cancer tissues, and a component part ARHGAP12 is significantly up-regulated in the gastric cancer and is related to tumor infiltration depth; a function experiment shows that ARHGAP12 can promote gastric cancer cell proliferation, migration and invasion; survival analysis shows that high expression of ARHGAP12 is significantly related to poor prognosis of patients. Based on the above findings, the kit can be used for early diagnosis and prognosis evaluation of the gastric cancer, and has a good clinical application prospect.

The application discloses a kind of simultaneously resistant glufosinate and 2,4-D class herbicide fusion gene, expression vector and application, the core innovation of the application is in that first aromatic oxyalkanoic acid dioxygenase gene, glufosinate acetyltransferase gene is functionally fused, constructs a kind of new herbicide-resistant fusion gene, the gene not only can simultaneously give plant to glufosinate and 2,4-D class herbicide double resistance, also makes resistance level compared to single gene expression respectively increases by 8%-10%, and under high expression condition, the inhibition rate of plant growth is reduced by about 15%, significantly widen the selection range of field herbicide, improve the safety and profitability of crop planting.

This invention belongs to the field of biomedical technology and relates to a fusion protein, gene, expression vector, genetically engineered bacteria, and their applications. The fusion protein is derived from the fusion of bacterial outer membrane vesicle protein and human PD-L1, or from the fusion of bacterial outer membrane vesicle protein, human PD-L1, and human Fc protein. Genetically engineered bacteria constructed using the fusion gene provided by this invention can release PD-L1-rich outer membrane vesicles, which can effectively penetrate the lamina propria of the mucosa and regulate inflammation inside and outside the intestine. This genetically engineered bacterium exhibits good biosafety, effectively regulating intestinal flora and metabolism, and improving intestinal barrier function; moreover, it shows good oral administration compliance, which is beneficial for clinical trials.

The application belongs to the field of synthetic biology and genetic engineering, and particularly relates to a Saccharomyces cerevisiae strain and a construction method and application thereof. The strain is Saccharomyces cerevisiae WZ 214, which is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M20251331, and the preservation date is June 10, 2025. A fusion gene is constructed by fusing a key enzyme gene (Nampt and PRPS) for synthesizing β-NMN and a yeast surface anchoring protein gene, and a recombinant strain displaying the key enzyme on the surface is obtained by transforming the original Saccharomyces cerevisiae. Then, the FYV5 gene of the recombinant strain is knocked out to optimize the cell wall structure and reduce the product secretion resistance. The application effectively solves the problems of intracellular product accumulation, great separation difficulty and low production efficiency in the prior art, and provides new technical support for efficient and green production of β-NMN.

This invention discloses a high-glutathione-producing engineered Escherichia coli strain and its applications, belonging to the field of biotechnology; the engineered Escherichia coli strain is named ZMGSH01F, with accession number CCTCC M 20252236; the engineered Escherichia coli strain is based on Escherichia coli BL21(DE3) as the starting strain, with gene clusters knocked out. ptsH‐ ptsI‐crr And integrate at this site glf‐glk Fusion genes, knockout gene clusters gsiA‐gsiB‐gsiC Integrate the endogenous glutathione transporter gene at this site. cycDC Knockout of γ-glutamyltransferase gene ggt Simultaneously expressing the recombinant plasmid pRSFDuet- gshAB K177E‑E275K‑V513A - ppk2 The engineered Escherichia coli strain can efficiently produce glutathione through fermentation culture using glucose, monosodium glutamate, cysteine, and glycine as substrates.

The application discloses application of a detection reagent in detection of ZM fusion gene (PTPRZ1-MET fusion gene) positive secondary glioblastoma (sGBM), and belongs to the technical field of biological medicine, so as to solve the problems of the existing ZM fusion detection method, such as complex operation, poor specificity, and unsuitability for routine clinical detection. Based on high-throughput RNA sequencing and machine learning algorithm (XGBoost) analysis, it is found for the first time that the combined expression profile of three genes, MET, PCDHGA3 and FAM3C, can significantly distinguish ZM fusion positive and negative samples, and the diagnostic accuracy (AUC) is as high as 99.8%, with high sensitivity and specificity. The detection product of the application is suitable for paraffin-embedded (FFPE) pathological tissue samples and frozen samples, and can complete the detection in combination with mature platforms such as multiplex immunohistochemistry or high-throughput RNA sequencing, and has good sample compatibility and operation feasibility.

The present application relates to the field of disease prediction in bioinformatics, and particularly relates to a cognitive disease classification method based on gene communication mode and multi-view learning. The present application uses a gene network reasoning algorithm to operate on the screened sample-gene expression matrix to obtain a gene regulatory network; combines the importance score of the gene regulatory network and the gene module information to obtain a gene module communication tensor; respectively extracts features from the gene module communication tensor and the sample-gene expression matrix, and puts the extracted features into a Transformer encoder and an interleaved decoder for feature fusion to obtain odd layer and even layer features, splices the features of the two layers and puts them into a multi-layer perceptron to finally classify Alzheimer's disease into different stages. The present application provides a neural network framework for double-view learning of gene communication analysis of Alzheimer's disease, fuses two-view information of gene module communication tensor and transcriptome, and improves the accuracy of brain disease stage classification.

This invention discloses a generative AI diagnostic and treatment platform that integrates gene data and clinical images, belonging to the field of medical technology. It includes modules for data acquisition, desensitization and protection, data processing, feature extraction, gene analysis, fusion analysis, predictive analysis, treatment plan generation, result display, model management, self-iteration, and user management. This invention enables non-invasive and accurate diagnosis, reducing potential harm to newborns, minimizing unnecessary repeat examinations, lowering overall diagnostic costs, and improving the stability and accuracy of disease prediction results. Simultaneously, this invention enhances the foresight and scientific rigor of treatment plan development, providing strong support for early intervention and precision medicine, improving diagnostic efficiency and risk assessment accuracy, and saving hospitals and patients significant time and effort.

This invention discloses an engineered astaxanthin-producing probiotic yeast strain, its construction method, and its applications, belonging to the field of synthetic biology. The engineered strain uses β-carotene-producing *Saccharomyces cerevisiae* as the substrate cell. Its genome integrates a fusion gene selected through adaptability screening. This gene is composed of *BDC263crtW* from *Saccharomyces cerevisiae*, a flexible linker peptide, and *AspcrtZ* from *Alcaligenes aeruginosa*, linked sequentially. Simultaneously, based on systematic expression screening of multiple key genes, the endogenous acetyl-CoA synthesis key gene ACS1 was optimized and overexpressed, while the acetic acid metabolism negative regulatory gene YPL062W was knocked out. The construction method includes plasmid construction of the aforementioned fusion expression module and ACS1 expression module, and targeted integration into the genome. This invention significantly improves astaxanthin synthesis levels and enhances the engineered strain's tolerance to the simulated gastrointestinal environment and its antioxidant capacity through enzyme source optimization and substrate channel effects. This engineered strain can be directly used as a functional live bacteria preparation for food and feed additives, with broad prospects for industrial application.

Compositions and methods for knocking down the expression of an EWSR1-ATF1 fusion gene and / or an EWSR1-CREB1 fusion gene in a subject are disclosed herein. In some embodiments, the composition comprises an expression vector comprising a bifunctional short hairpin RNA (bi-shRNA) sequence specific for knockdown of an EWSR1-ATF1 fusion gene and / or an EWSR1-CREB1 fusion gene.

This invention relates to a recombinant *Lactococcus lactis* microcapsule, its preparation method, and its applications, belonging to the field of genetic engineering. To address the technical problems of low safety, high side effects, unstable efficacy, and insufficient targeting in existing methods for treating or alleviating inflammatory bowel disease (IBD), this invention provides a recombinant *Lactococcus lactis* microcapsule. By integrating a fusion gene encoding catalase and superoxide dismutase, a recombinant *Lactococcus lactis* with antioxidant function is constructed. The recombinant *Lactococcus lactis* is then coated with a mucosa-adhesive chitosan and sodium alginate composite nanomaterial to obtain a microcapsule with antioxidant enzyme expression capabilities and a nano-protective coating. The recombinant *Lactococcus lactis* microcapsule provided by this invention can enhance the activity and bioavailability of orally delivered substances under the harsh acidic environment and complex physiological barriers of the gastrointestinal tract, providing a new strategy and experimental evidence for the clinical prevention and treatment of IBD.

The present invention relates to a drug for treating or preventing ALK fusion gene-positive cancer positive for FGFR1 expression and positive for FGF2 expression at baseline, the drug comprising a compound having ALK inhibitory activity and a FGFR inhibitor in combination, a combination agent, a pharmaceutical composition, a preparation, a treatment or prevention method, or a drug for suppressing acquisition of resistance, a method for selecting a patient, and the like.

This invention relates to a nanopore sequencing detection method for sarcoma EWS-ETS fusion genes based on single-end primers. It designs an amplification strategy combining a 3' gene-specific single primer with a universal primer, leveraging the long read advantage of nanopore sequencing. A complete detection workflow is constructed, encompassing sample pretreatment, nucleic acid extraction, single-end primer amplification, nanopore library construction and sequencing, and fusion gene identification. The clinical application pathway is also clearly defined. This invention eliminates the need for prior knowledge of the fusion partner gene, significantly improving the detection sensitivity of rare EWS-ETS fusion genes. It offers high breakpoint localization accuracy and standardized procedures, enabling efficient screening and confirmation of sarcoma fusion genes, providing reliable technical support for accurate diagnosis, prognostic assessment, and targeted therapy of sarcoma.

This disclosure provides a method, system, device, and medium for grading sequencing data. The grading method includes: acquiring targeted sequencing data; performing data preprocessing on the targeted sequencing data to obtain sample sequences; identifying fusion genes in the sample sequences to determine if fusion genes exist, obtaining fusion gene identification results; and performing clonal rearrangement identification on the sample sequences to determine if a master clone exists; calculating fusion gene scores based on the fusion gene identification results; and grading the sample sequences based on the fusion gene scores and the clonal rearrangement identification results.

This invention discloses a biomimetic recombinant V-type mussel adhesive protein, its preparation method, and its applications. The recombinant V-type mussel adhesive protein is composed of the Mfp-5 protein from natural mussels and proteins that constitute the fibrous skeleton of mussel byssal fibers. During preparation, the fusion gene and a tyrosinase gene are co-expressed, and the expressed tyrosinase is used to modify the tyrosine residues in the recombinant mussel adhesive protein with dopa, thereby obtaining a bioactive recombinant V-type mussel adhesive protein with high yield, high purity, and low endotoxin content, fully meeting the application requirements of pharmaceuticals, medical devices, and cosmetics.

This invention relates to the field of biotechnology and provides a gene-modified mouse model for tracking migratory organisms, its construction method, and its applications. The invention achieves precise labeling of endogenous migratory organisms by fusing the key structural protein TSPAN4 of the migratory organism with the fluorescent tag RFP and the modification tag Avi-tag, and site-specifically integrating it into the H11 site of mice, thus obtaining a TSPAN4-overexpressing transgenic mouse model. By introducing an LSL structure, the fusion gene is kept in a state of expression shutdown, achieving temporal and spatial specific activation only after mating with tissue-specific Cre tool mice. Multidimensional validation has shown that this model can accurately track migratory organisms in placental trophoblast cells, providing a standardized tool for assessing disease progression under physiological and pathological conditions through differences in migratory organism trajectory, inclusion packaging, and assembly, and can be directly applied to mechanistic studies and drug screening for diseases such as adverse pregnancy outcomes.

This invention discloses a bifunctional engineered magnetotactic bacterium. The engineered magnetotactic bacterium is constructed using a recombinant PmamC-MamC-(Gly₄Ser)₃-MagLov fusion gene fragment to construct the expression plasmid pBBR1-MagLov-MamC. Using Magnetospirillum gryphiswaldense MSR-1 as a host, the recombinant expression plasmid pBBR1-MagLov-MamC is conjugated to obtain the bifunctional engineered magnetotactic bacterium MSR-1-MagLov capable of expressing the MagLov-MamC fusion protein. This invention also discloses the construction method and its applications. This invention overcomes the technical bias of exogenous proteins inhibiting magnetosome synthesis, achieving the integration of magnetotactic motility and magnetosensitive fluorescence.